Connect with us

Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO

Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO

Published

on

Kristen Buck

→ Prominent CRO player Icon is bolstering its leadership, with Kristen Buck taking the reins as CMO.

For slightly more than a year and a half, Buck was the SVP & chief of clinical development at Optum, part of the UnitedHealth conglomerate. When she got there, she had already held a post at the FDA in the gastrointestinal and hematology division, tasked with post-marketing safety for over 40 drugs. She had also spent 6 years as an exec at AstraZeneca in clinical development and in its innovative medicines group.

Her background covers an array of therapy areas, including GI, women’s health, ophthalmology, neuroscience, dermatology, oncology, liver, orphan diseases and psychiatry.

Buck was a track and field athlete at the University of Virginia and then moved on to Penn State to receive her MD. She stayed in Pennsylvania to complete her internship and residency in internal medicine at Abington Memorial Hospital.

Dublin-based Icon won Best Contract Research Organization (full-service providers) in December at the Scrip Awards in London.

“I’m excited to be leading ICON’s position on clinical development trends, and reviewing and advising on our medical risks as the world wrestles with the Covid-19 pandemic,” Buck said in a statement. “Patient centricity is ever more important in the current climate and I look forward to working with the wider ICON team to broaden our insights and expand our expertise.”

Brian DiDonato has jumped in as CFO and head of strategy of TCR-focused Immunocore, which is moving on from Neil Woodford after scoring a $130 billion Series B haul in March. DiDonato was most recently the SVP and CFO at Achillion Pharmaceuticals, acquired by Alexion. Other previous stops for DiDonato include Sorin Capital Management, Capmark Investments as president and chief investment officer, Morgan Stanley and UBS Securities.

→ While working towards its goal of producing 1 billion vaccines to fight Covid-19, as well as being the company with one of the leading vaccines now in the clinic, Moderna has ramped up its team with some new appointments. This comes after news of their CFO Lorence Kim hitting the exit after 6 years with the Boston-based upstart. Patrick Bergstedt, Jacqueline Miller and Charbel Haber have all hopped aboard to help with the company’s lightning-fast campaign. Bergstedt, a Merck vet, is stepping in as SVP for commercial vaccines; Miller hails from GSK and comes in as SVP of infectious disease development and Haber, meanwhile, leaps over from Biogen as SVP of regulatory affairs.

Najat Khan

→ Over at J&J, Najat Khan has transitioned into the role of chief data science officer. Previously, Khan had served as the COO in the research arm. R&D chief Mathai Mammen praised Khan for her bilingual expertise in two key languages: the science of drug development as well as data sciences. And handled properly, that can guide R&D to more wins with lower costs — a longtime mantra in a world where ROI is generally sorely lacking. Prior to jumpstarting her role at J&J, Khan served as a pharma consultant at the Boston Consulting Group.

→ Singapore biotech Tessa Therapeutics, which focuses on cancer cell therapies, has undergone a few leadership changes. Andrew Khoo has stepped aside as CEO but will remain on Tessa’s board, and Jeffrey Buchalter, a board member since last March, has succeeded him. Buchalter has been president and CEO of Archimedes Pharmaceuticals, Enzon Pharmaceuticals and Ilex Oncology. Chairman of the board Teo Ming Kian also stepped down effective May 1, with former Novo Nordisk chairman Göran Ando set to take his place.

Jeffrey Buchalter

→ Expanding his role at CNS-focused Impel NeuroPharma, Adrian Adams is now the chairman and CEO effective immediately, replacing Jon Congleton. Adams was named chairman of Impel’s board in January, and before then, he held numerous CEO posts, including at Aralez Pharmaceuticals, Auxilium Pharmaceuticals (until its acquisition by Endo International plc) and Neurologix.

→ Along with changing its name, Trovagene is doing some C-suite shuffling. Now called Cardiff Oncology, the San Diego-based precision cancer meds company developing the cancer drug onvansertib is promoting Mark Erlander to CEO, while Thomas Adams transitions from chairman and CEO to executive chairman. Erlander had been the former Trovagene’s CSO since 2013.

Mark Erlander

Timothy Jones will lead RespireRx Pharmaceuticals as president and CEO, replacing Arnold Lippa, who served in those capacities on an interim basis. Lippa stays on as executive chairman and CSO. Since January, Jones had been on the board of RespireRx, which targets treatment options for such conditions as obstructive sleep apnea and ADHD, and orphan diseases such as Fragile X syndrome. Jones heads to RespireRx from Purisys, where he was VP of global pharmaceutical and medical OTC.

Rajiv Khosla has been selected as CEO of NJ-based Enteris BioPharma, replacing Joel Tune, who had been CEO the last four years. Before he began at Enteris, which developed oral delivery technology called Peptelligence, Khosla founded Ceutec, a business development consultancy that served biopharmas and VCs. He was also at Biovail as VP of business development.

Tony Gibney

→ Last year around this time, FogPharma introduced CSO Howard Stern. This week the Massachusetts biotech has a new CFO and CBO in Tony Gibney, the former EVP and CBO of Achillion who led the company’s sale to Alexion. Before Achillion, Gibney’s life science investment banking experience includes stints at Leerink Partners, Merrill Lynch and Lehman Brothers.

→ Milan-based PinCell, which targets rare dermatological diseases and raised €1.65 million in seed financing led by Sofinnova Partners, has named Gabriella Camboni as CEO and will be a member of the board of directors. Nordic Nanovector CEO Luigi Costa has also been pegged as chairman of PinCell’s board, and Paola Pozzi, a partner at Sofinnova Partners, will also join as a board member.

Christine Matthews

→ With the FDA accepting the NDA for its migraine drug Qtrypta in March, Zosano Pharma has selected Christine Matthews as CFO. She was the California biopharma’s interim CFO since February and was an accounting and financial consultant with RGP before her time with Zosano. Matthews was also director of financial planning & analysis at Cepheid and began her career at Arthur Andersen.

Douglas Pagán is moving to Dicerna to become CFO, effective May 26. Before joining Dicerna, which announced an RNAi collaboration with Alnylam in April for alpha 1 liver disease, Pagán will wrap up his tenure as CFO and secretary of KSQ Therapeutics. Prior to that, he was CFO of Paratek Pharmaceuticals for five years.

→ A couple of new moves have been made at Spruce Biosciences, which released positive results in September from its Phase II study of its lead candidate tildacerfont in adults with congenital adrenal hyperplasia. Samir Gharib joins the team as CFO, coming from Stemedica Cell Technologies where he had the same role. Meanwhile, Dasharatha Reddy is on board as VP of pharmaceutical development and manufacturing. She was previously head of CMC at Landos Biopharma.

Andrew Guggenhime

→ Fresh off $100 million Series D financing to help take its Prevnar 13 rival SVX-24 to the clinic, SutroVax has welcomed Andrew Guggenhime as CFO and CBO. Guggenhime was Demira’s CFO from 2014 until Eli Lilly acquired the company in February. He has a plethora of other CFO roles to his credit, including at CardioDx, Calistoga Pharmaceuticals and Facet Biotech Corporation.

→ Cancer therapy-focused Anchiano is appointing Steve DiPalma as its CFO. DiPalma had been a senior financial advisor to Cambridge, MA-based Anchiano the last two years, in accordance with Danforth Advisors. His predecessor, Jonathan Burgin, is leaving as the biotech closes its Israel offices and facilities. DiPalma has held leadership roles at numerous companies, including Forum Pharmaceuticals, RXi Pharmaceuticals, and at Catalyst Oncology, where he was president and CEO.

→ Former Pfizer exec Robert Foerster has signed on to be CFO at Oligomerix, a Bronx biotech developing novel therapeutics for Alzheimer’s disease and related neurodegenerative disorders. During his tenure with the pharma giant, Foerster assumed such roles as senior director, commercial development for emerging markets and senior director of Pfizer Japan’s business development division.

→ With its Neutrox family of products that includes Avenova and CelleRx, NovaBay Pharmaceuticals has a new CFO. Andrew Jones has jumped on board to replace the interim CFO, Lynn Christopher, who continues in a consultancy role. Jones was previously VP, finance of MyoScience for a little over a year until Pacira BioSciences acquired it last August.

→ Speaking of Pacira Biosciences, which focuses on non-opioid treatments, the company has brought in Donald Manning to be CMO. Manning had been CMO of Adynxx since 2012, and he also held positions at Novartis (global head of analgesics development) and Celgene (VP and neurosciences therapeutic area head).

Noreen Henig

→ After CMO stints at Breath Therapeutics and ProQR Therapeutics, Noreen Henig is taking on the same CMO role at Kezar Life Sciences, which focuses on treatments for autoimmune diseases and cancer. Prior to ProQR, Henig spent six years at Gilead, notably as senior director, global medical affairs, respiratory and PAH.

→ Palo Alto-based LifeMax Laboratories, which in April was granted fast track designation for LM-030 licensed from Novartis and in a Phase II/III pivotal clinical trial for treating Netherton syndrome, has tapped Michael Huang as its CMO. Huang was CMO of Spruce Biosciences and was previously VP of clinical development at both Regulus Therapeutics and Auspex Pharmaceuticals.

GSK vet Ian Catchpole has landed the CSO position at Horama after some consulting work and a gig as director of research at TC Biopharm. Catchpole was at GSK for 25 years, capping his tenure as “cell and gene therapy discovery” translational leader and by being named a GSK Fellow in 2016. His expertise also extends to ophthalmology, vaccination and immuno-oncology.

Elaine Jones

→ Los Angeles biotech Myst Therapeutics, which develops selected TIL-based autologous T cell (PuriT) therapy products for cancer, has tapped George Smith as VP of business operations. Smith was the founder and integrated program lead at Iqvia’s Gene Therapy Center and their senior director, portfolio and innovation.

→ Immunotherapy-focused Gritstone Oncology has appointed Elaine Jones as chair of the board of directors. From 2008 to 2019, Jones was vice president, worldwide business development and senior partner at Pfizer Ventures and has been general partner at EuclidSR Partners.

Nordic Nanovector is reshuffling its exec team in an effort of cost-saving initiatives announced in early April. CFO Tone Kvåle and chief human resources officer Rita Dege have parted ways with the company. Meanwhile, Malene Brondberg, VP investor relations and corporation communications, has been appointed CFO. Brondberg joined the company in February 2018 and brought experience from her time with The restructuring has reduced the number of executives from nine to seven.

Codexis has filled two newly-created positions. Stefan Lutz has stepped in as SVP, research, and Karl Schoene is also diving in as SVP, development and operations. Lutz was a professor and chair of the chemistry department at Emory, while Schoene had previously been president, CEO and director of Elevance Renewable Sciences.

→ Partnering with Pfizer on its antisense therapy AKCEA-ANGPTL3-LRx, Akcea Therapeutics has chosen Carla Poulson as SVP and chief human resources officer. Poulson makes the transition to Akcea, majority owned by Ionis, from Vertex, where she was VP, senior human resources business partner.

Stephen Migausky Imara

→ After the announcement of their CMO hitting the exit late last month, NEA-founded Imara has added Stephen Migausky to the ranks as SVP, legal and general counsel. Prior to joining Imara, Migausky served as general counsel at ArQule and has previously served in roles at Vertex.

Scott Byrd, Ian Mills and Gordon McMurray have joined Frazier Healthcare Partners as entrepreneur-in-residence consultants. The three were previously a part of the management team at Frazier portfolio company Outpost Medicine and served as CEO, CMO and CSO respectively. They have recently formed Pioneer Therapeutics. Formerly, Byrd was president and COO at Acacia Pharma; Mills was head of clinical development at Mitsubishi Tanabe Pharma Europe and McMurray had a stint at Pfizer Global R&D.

→ Next-gen T cell player TCR² Therapeutics — which snagged a $75M IPO last year — has added Stephen Webster, the former CFO of Spark Therapeutics, to its board of directors. Webster will take over for Mitchell Finer who is stepping down from the board.

Stephen Webster

→ After raising $200M-plus for their IPO in February, drug discovery software player Schrödinger has welcomed Jeffrey Chodakewitz and Gary Ginsberg to its board of directors. Chodakewitz previously held posts at Vertex and Merck, while Ginsberg served stints at Time Warner and Softbank Group.

ALX Oncology, which develops therapies that block the CD47 checkpoint pathway, has appointed Rekha Hemrajani to its board of directors. Hemrajani is the president and CEO of Aravive and the former COO and CFO of Arcus Biosciences.

Recursion, which bills itself as the first AI biotech to launch human trials, has enlisted R Martin Chavez and Terry-Ann Burrell to its board of directors. Chavez is the former CFO, chief information officer and global co-head of the securities division at Goldman Sachs and Burrell currently serves as CFO of Beam Therapeutics.

Read More

Continue Reading

Government

Are Voters Recoiling Against Disorder?

Are Voters Recoiling Against Disorder?

Authored by Michael Barone via The Epoch Times (emphasis ours),

The headlines coming out of the Super…

Published

on

Are Voters Recoiling Against Disorder?

Authored by Michael Barone via The Epoch Times (emphasis ours),

The headlines coming out of the Super Tuesday primaries have got it right. Barring cataclysmic changes, Donald Trump and Joe Biden will be the Republican and Democratic nominees for president in 2024.

(Left) President Joe Biden delivers remarks on canceling student debt at Culver City Julian Dixon Library in Culver City, Calif., on Feb. 21, 2024. (Right) Republican presidential candidate and former U.S. President Donald Trump stands on stage during a campaign event at Big League Dreams Las Vegas in Las Vegas, Nev., on Jan. 27, 2024. (Mario Tama/Getty Images; David Becker/Getty Images)

With Nikki Haley’s withdrawal, there will be no more significantly contested primaries or caucuses—the earliest both parties’ races have been over since something like the current primary-dominated system was put in place in 1972.

The primary results have spotlighted some of both nominees’ weaknesses.

Donald Trump lost high-income, high-educated constituencies, including the entire metro area—aka the Swamp. Many but by no means all Haley votes there were cast by Biden Democrats. Mr. Trump can’t afford to lose too many of the others in target states like Pennsylvania and Michigan.

Majorities and large minorities of voters in overwhelmingly Latino counties in Texas’s Rio Grande Valley and some in Houston voted against Joe Biden, and even more against Senate nominee Rep. Colin Allred (D-Texas).

Returns from Hispanic precincts in New Hampshire and Massachusetts show the same thing. Mr. Biden can’t afford to lose too many Latino votes in target states like Arizona and Georgia.

When Mr. Trump rode down that escalator in 2015, commentators assumed he’d repel Latinos. Instead, Latino voters nationally, and especially the closest eyewitnesses of Biden’s open-border policy, have been trending heavily Republican.

High-income liberal Democrats may sport lawn signs proclaiming, “In this house, we believe ... no human is illegal.” The logical consequence of that belief is an open border. But modest-income folks in border counties know that flows of illegal immigrants result in disorder, disease, and crime.

There is plenty of impatience with increased disorder in election returns below the presidential level. Consider Los Angeles County, America’s largest county, with nearly 10 million people, more people than 40 of the 50 states. It voted 71 percent for Mr. Biden in 2020.

Current returns show county District Attorney George Gascon winning only 21 percent of the vote in the nonpartisan primary. He’ll apparently face Republican Nathan Hochman, a critic of his liberal policies, in November.

Gascon, elected after the May 2020 death of counterfeit-passing suspect George Floyd in Minneapolis, is one of many county prosecutors supported by billionaire George Soros. His policies include not charging juveniles as adults, not seeking higher penalties for gang membership or use of firearms, and bringing fewer misdemeanor cases.

The predictable result has been increased car thefts, burglaries, and personal robberies. Some 120 assistant district attorneys have left the office, and there’s a backlog of 10,000 unprosecuted cases.

More than a dozen other Soros-backed and similarly liberal prosecutors have faced strong opposition or have left office.

St. Louis prosecutor Kim Gardner resigned last May amid lawsuits seeking her removal, Milwaukee’s John Chisholm retired in January, and Baltimore’s Marilyn Mosby was defeated in July 2022 and convicted of perjury in September 2023. Last November, Loudoun County, Virginia, voters (62 percent Biden) ousted liberal Buta Biberaj, who declined to prosecute a transgender student for assault, and in June 2022 voters in San Francisco (85 percent Biden) recalled famed radical Chesa Boudin.

Similarly, this Tuesday, voters in San Francisco passed ballot measures strengthening police powers and requiring treatment of drug-addicted welfare recipients.

In retrospect, it appears the Floyd video, appearing after three months of COVID-19 confinement, sparked a frenzied, even crazed reaction, especially among the highly educated and articulate. One fatal incident was seen as proof that America’s “systemic racism” was worse than ever and that police forces should be defunded and perhaps abolished.

2020 was “the year America went crazy,” I wrote in January 2021, a year in which police funding was actually cut by Democrats in New York, Los Angeles, San Francisco, Seattle, and Denver. A year in which young New York Times (NYT) staffers claimed they were endangered by the publication of Sen. Tom Cotton’s (R-Ark.) opinion article advocating calling in military forces if necessary to stop rioting, as had been done in Detroit in 1967 and Los Angeles in 1992. A craven NYT publisher even fired the editorial page editor for running the article.

Evidence of visible and tangible discontent with increasing violence and its consequences—barren and locked shelves in Manhattan chain drugstores, skyrocketing carjackings in Washington, D.C.—is as unmistakable in polls and election results as it is in daily life in large metropolitan areas. Maybe 2024 will turn out to be the year even liberal America stopped acting crazy.

Chaos and disorder work against incumbents, as they did in 1968 when Democrats saw their party’s popular vote fall from 61 percent to 43 percent.

Views expressed in this article are opinions of the author and do not necessarily reflect the views of The Epoch Times or ZeroHedge.

Tyler Durden Sat, 03/09/2024 - 23:20

Read More

Continue Reading

Government

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The…

Published

on

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The U.S. Department of Veterans Affairs (VA) reviewed no data when deciding in 2023 to keep its COVID-19 vaccine mandate in place.

Doses of a COVID-19 vaccine in Washington in a file image. (Jacquelyn Martin/Pool/AFP via Getty Images)

VA Secretary Denis McDonough said on May 1, 2023, that the end of many other federal mandates “will not impact current policies at the Department of Veterans Affairs.”

He said the mandate was remaining for VA health care personnel “to ensure the safety of veterans and our colleagues.”

Mr. McDonough did not cite any studies or other data. A VA spokesperson declined to provide any data that was reviewed when deciding not to rescind the mandate. The Epoch Times submitted a Freedom of Information Act for “all documents outlining which data was relied upon when establishing the mandate when deciding to keep the mandate in place.”

The agency searched for such data and did not find any.

The VA does not even attempt to justify its policies with science, because it can’t,” Leslie Manookian, president and founder of the Health Freedom Defense Fund, told The Epoch Times.

“The VA just trusts that the process and cost of challenging its unfounded policies is so onerous, most people are dissuaded from even trying,” she added.

The VA’s mandate remains in place to this day.

The VA’s website claims that vaccines “help protect you from getting severe illness” and “offer good protection against most COVID-19 variants,” pointing in part to observational data from the U.S. Centers for Disease Control and Prevention (CDC) that estimate the vaccines provide poor protection against symptomatic infection and transient shielding against hospitalization.

There have also been increasing concerns among outside scientists about confirmed side effects like heart inflammation—the VA hid a safety signal it detected for the inflammation—and possible side effects such as tinnitus, which shift the benefit-risk calculus.

President Joe Biden imposed a slate of COVID-19 vaccine mandates in 2021. The VA was the first federal agency to implement a mandate.

President Biden rescinded the mandates in May 2023, citing a drop in COVID-19 cases and hospitalizations. His administration maintains the choice to require vaccines was the right one and saved lives.

“Our administration’s vaccination requirements helped ensure the safety of workers in critical workforces including those in the healthcare and education sectors, protecting themselves and the populations they serve, and strengthening their ability to provide services without disruptions to operations,” the White House said.

Some experts said requiring vaccination meant many younger people were forced to get a vaccine despite the risks potentially outweighing the benefits, leaving fewer doses for older adults.

By mandating the vaccines to younger people and those with natural immunity from having had COVID, older people in the U.S. and other countries did not have access to them, and many people might have died because of that,” Martin Kulldorff, a professor of medicine on leave from Harvard Medical School, told The Epoch Times previously.

The VA was one of just a handful of agencies to keep its mandate in place following the removal of many federal mandates.

“At this time, the vaccine requirement will remain in effect for VA health care personnel, including VA psychologists, pharmacists, social workers, nursing assistants, physical therapists, respiratory therapists, peer specialists, medical support assistants, engineers, housekeepers, and other clinical, administrative, and infrastructure support employees,” Mr. McDonough wrote to VA employees at the time.

This also includes VA volunteers and contractors. Effectively, this means that any Veterans Health Administration (VHA) employee, volunteer, or contractor who works in VHA facilities, visits VHA facilities, or provides direct care to those we serve will still be subject to the vaccine requirement at this time,” he said. “We continue to monitor and discuss this requirement, and we will provide more information about the vaccination requirements for VA health care employees soon. As always, we will process requests for vaccination exceptions in accordance with applicable laws, regulations, and policies.”

The version of the shots cleared in the fall of 2022, and available through the fall of 2023, did not have any clinical trial data supporting them.

A new version was approved in the fall of 2023 because there were indications that the shots not only offered temporary protection but also that the level of protection was lower than what was observed during earlier stages of the pandemic.

Ms. Manookian, whose group has challenged several of the federal mandates, said that the mandate “illustrates the dangers of the administrative state and how these federal agencies have become a law unto themselves.”

Tyler Durden Sat, 03/09/2024 - 22:10

Read More

Continue Reading

Spread & Containment

The Coming Of The Police State In America

The Coming Of The Police State In America

Authored by Jeffrey Tucker via The Epoch Times,

The National Guard and the State Police are now…

Published

on

The Coming Of The Police State In America

Authored by Jeffrey Tucker via The Epoch Times,

The National Guard and the State Police are now patrolling the New York City subway system in an attempt to do something about the explosion of crime. As part of this, there are bag checks and new surveillance of all passengers. No legislation, no debate, just an edict from the mayor.

Many citizens who rely on this system for transportation might welcome this. It’s a city of strict gun control, and no one knows for sure if they have the right to defend themselves. Merchants have been harassed and even arrested for trying to stop looting and pillaging in their own shops.

The message has been sent: Only the police can do this job. Whether they do it or not is another matter.

Things on the subway system have gotten crazy. If you know it well, you can manage to travel safely, but visitors to the city who take the wrong train at the wrong time are taking grave risks.

In actual fact, it’s guaranteed that this will only end in confiscating knives and other things that people carry in order to protect themselves while leaving the actual criminals even more free to prey on citizens.

The law-abiding will suffer and the criminals will grow more numerous. It will not end well.

When you step back from the details, what we have is the dawning of a genuine police state in the United States. It only starts in New York City. Where is the Guard going to be deployed next? Anywhere is possible.

If the crime is bad enough, citizens will welcome it. It must have been this way in most times and places that when the police state arrives, the people cheer.

We will all have our own stories of how this came to be. Some might begin with the passage of the Patriot Act and the establishment of the Department of Homeland Security in 2001. Some will focus on gun control and the taking away of citizens’ rights to defend themselves.

My own version of events is closer in time. It began four years ago this month with lockdowns. That’s what shattered the capacity of civil society to function in the United States. Everything that has happened since follows like one domino tumbling after another.

It goes like this:

1) lockdown,

2) loss of moral compass and spreading of loneliness and nihilism,

3) rioting resulting from citizen frustration, 4) police absent because of ideological hectoring,

5) a rise in uncontrolled immigration/refugees,

6) an epidemic of ill health from substance abuse and otherwise,

7) businesses flee the city

8) cities fall into decay, and that results in

9) more surveillance and police state.

The 10th stage is the sacking of liberty and civilization itself.

It doesn’t fall out this way at every point in history, but this seems like a solid outline of what happened in this case. Four years is a very short period of time to see all of this unfold. But it is a fact that New York City was more-or-less civilized only four years ago. No one could have predicted that it would come to this so quickly.

But once the lockdowns happened, all bets were off. Here we had a policy that most directly trampled on all freedoms that we had taken for granted. Schools, businesses, and churches were slammed shut, with various levels of enforcement. The entire workforce was divided between essential and nonessential, and there was widespread confusion about who precisely was in charge of designating and enforcing this.

It felt like martial law at the time, as if all normal civilian law had been displaced by something else. That something had to do with public health, but there was clearly more going on, because suddenly our social media posts were censored and we were being asked to do things that made no sense, such as mask up for a virus that evaded mask protection and walk in only one direction in grocery aisles.

Vast amounts of the white-collar workforce stayed home—and their kids, too—until it became too much to bear. The city became a ghost town. Most U.S. cities were the same.

As the months of disaster rolled on, the captives were let out of their houses for the summer in order to protest racism but no other reason. As a way of excusing this, the same public health authorities said that racism was a virus as bad as COVID-19, so therefore it was permitted.

The protests had turned to riots in many cities, and the police were being defunded and discouraged to do anything about the problem. Citizens watched in horror as downtowns burned and drug-crazed freaks took over whole sections of cities. It was like every standard of decency had been zapped out of an entire swath of the population.

Meanwhile, large checks were arriving in people’s bank accounts, defying every normal economic expectation. How could people not be working and get their bank accounts more flush with cash than ever? There was a new law that didn’t even require that people pay rent. How weird was that? Even student loans didn’t need to be paid.

By the fall, recess from lockdown was over and everyone was told to go home again. But this time they had a job to do: They were supposed to vote. Not at the polling places, because going there would only spread germs, or so the media said. When the voting results finally came in, it was the absentee ballots that swung the election in favor of the opposition party that actually wanted more lockdowns and eventually pushed vaccine mandates on the whole population.

The new party in control took note of the large population movements out of cities and states that they controlled. This would have a large effect on voting patterns in the future. But they had a plan. They would open the borders to millions of people in the guise of caring for refugees. These new warm bodies would become voters in time and certainly count on the census when it came time to reapportion political power.

Meanwhile, the native population had begun to swim in ill health from substance abuse, widespread depression, and demoralization, plus vaccine injury. This increased dependency on the very institutions that had caused the problem in the first place: the medical/scientific establishment.

The rise of crime drove the small businesses out of the city. They had barely survived the lockdowns, but they certainly could not survive the crime epidemic. This undermined the tax base of the city and allowed the criminals to take further control.

The same cities became sanctuaries for the waves of migrants sacking the country, and partisan mayors actually used tax dollars to house these invaders in high-end hotels in the name of having compassion for the stranger. Citizens were pushed out to make way for rampaging migrant hordes, as incredible as this seems.

But with that, of course, crime rose ever further, inciting citizen anger and providing a pretext to bring in the police state in the form of the National Guard, now tasked with cracking down on crime in the transportation system.

What’s the next step? It’s probably already here: mass surveillance and censorship, plus ever-expanding police power. This will be accompanied by further population movements, as those with the means to do so flee the city and even the country and leave it for everyone else to suffer.

As I tell the story, all of this seems inevitable. It is not. It could have been stopped at any point. A wise and prudent political leadership could have admitted the error from the beginning and called on the country to rediscover freedom, decency, and the difference between right and wrong. But ego and pride stopped that from happening, and we are left with the consequences.

The government grows ever bigger and civil society ever less capable of managing itself in large urban centers. Disaster is unfolding in real time, mitigated only by a rising stock market and a financial system that has yet to fall apart completely.

Are we at the middle stages of total collapse, or at the point where the population and people in leadership positions wise up and decide to put an end to the downward slide? It’s hard to know. But this much we do know: There is a growing pocket of resistance out there that is fed up and refuses to sit by and watch this great country be sacked and taken over by everything it was set up to prevent.

Tyler Durden Sat, 03/09/2024 - 16:20

Read More

Continue Reading

Trending